The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer.
 
Maryann J. Kwa
Consulting or Advisory Role - Advanced Medical
Research Funding - Bristol-Myers Squibb (Inst)
 
Nancy Tray
No Relationships to Disclose
 
Francisco J. Esteva
Consulting or Advisory Role - Celltrion; Genentech/Roche; Novartis
Research Funding - Genentech/Roche (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Myriad Genetics (royalties)
Travel, Accommodations, Expenses - Celltrion
 
Yelena Novik
Speakers' Bureau - Lilly
Research Funding - Macrogenics (Inst)
 
James L. Speyer
No Relationships to Disclose
 
Ruth Oratz
No Relationships to Disclose
 
Marleen Iva Meyers
No Relationships to Disclose
 
Franco Muggia
Consulting or Advisory Role - Merck
 
Victor Ty
No Relationships to Disclose
 
Andrea Troxel
No Relationships to Disclose
 
Robert Schneider
Stock and Other Ownership Interests - CERENIS THERAPEUTICS; ENB Therapeutics; Kadmon; PTC Therapeutics; REGENXBIO (I)
Consulting or Advisory Role - eFFECTOR Therapeutics; Ipsen; PTC Therapeutics
Patents, Royalties, Other Intellectual Property - ENB Therapeutics
 
Sylvia Adams
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Merck
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst)